GIANLIFE.BO · BSE
Gian Life Care Limited
₹4.29
+4.89% (+₹0.2)
Prev. close
₹4.09
Volume
7,967
As of
20 Nov 2026
Price history
Analyst sentiment
No analyst stances in this range
0 analyst stances · last 90 days · one per analyst
Try a wider range — no analyst has covered this yet.
Explore by date range →Analyst opinions
Fundamentals
About Gian Life Care Limited
Gian Life Care Limited provides diagnostic and related healthcare tests and services primarily in India. It offers patient diagnosis, as well as prevention and wellness diagnosis services. The company also provides various types of tests, such as biochemistry, clinical pathology, coagulation, cytogenetics, cytology, hematology, etc. It serves patients, healthcare providers, hospitals, and corporate customers. The company was incorporated in 2018 and is based in Kanpur, India.
Details
Sector
Healthcare
Industry
Diagnostics & Research
CEO
Mr. Arun Kumar Gupta
Headquarters
Kanpur
Employees
24
Website
gianlifecare.orgExchange
View on BSE ↗Key stats
Market cap
₹4.40 Cr
Dividend yield
0.00%
EPS (TTM)
₹-0.94
Beta (1Y · daily vs NIFTY 50)
0.41
Beta (5Y · monthly vs NIFTY 50)
0.80
Shares float
50.92 L
EPS · quarter ended Dec 2025
₹0.10
Financial Performance
01 · Financials
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| ₹10.46 Cr | ₹15.93 Cr | ₹11.92 Cr | ₹13.12 Cr | ₹6.63 Cr | |
EBITDA | ₹3.34 Cr | ₹6.53 Cr | ₹2.52 Cr | ₹6.74 Cr | ₹1.18 Cr |
| ₹2.02 Cr | ₹4.37 Cr | ₹1.06 Cr | ₹4.15 Cr | ₹-3.72 L | |
Diluted EPS | ₹4.29 | ₹4.23 | ₹1.03 | ₹4.01 | ₹-0.04 |
Depreciation & amortisation, Pretax income, Tax provision, Interest expense have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| — | ₹23.06 Cr | ₹28.24 Cr | ₹32.64 Cr | ₹35.93 Cr | |
| — | ₹4.52 Cr | ₹4.58 Cr | ₹4.88 Cr | ₹5.84 Cr | |
Stockholders' equity | — | ₹14.03 Cr | ₹15.12 Cr | ₹19.26 Cr | ₹19.22 Cr |
Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, Total debt, Long-term debt, Current (short-term) debt, Others, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| — | ₹1.32 Cr | ₹2.22 Cr | ₹69.55 L | ₹26.53 L | |
Investing cash flow | — | ₹-46.86 L | ₹-94.03 L | ₹-31.53 L | ₹25.42 L |
| — | ₹1.49 Cr | ₹-36.64 L | ₹-16.03 L | ₹45.26 L | |
Capital expenditure | — | ₹-95.69 L | ₹-1.63 Cr | ₹-98.36 L | ₹-1.06 L |
End cash position | — | ₹4.85 Cr | ₹5.77 Cr | ₹5.99 Cr | ₹6.96 Cr |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt issued, Debt repaid, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.25 L Cr | ₹1,769.9 | 38.8 | 5.09 | 13.7% | 0.06 | +11.9% | +3.7% |
| Divi's Laboratories Limited | ₹2.66 L Cr | ₹10,037.5 | 90.8 | 15.85 | 15.3% | 0.00 | +12.3% | +47.5% |
| Torrent Pharmaceuticals Limited | ₹1.79 L Cr | ₹4,738.5 | 79.4 | 21.31 | 25.8% | 1.79 | +21.5% | +32.5% |
| Laurus Labs Limited | ₹1.27 L Cr | ₹2,348 | 94.8 | 23.94 | 16.8% | 0.48 | +22.0% | +146.2% |
| Apollo Hospitals Enterprise Limited | ₹1.23 L Cr | ₹8,599.5 | 58.8 | 12.95 | 20.5% | 0.90 | +15.7% | +10.1% |
| Zydus Lifesciences Limited | ₹1.19 L Cr | ₹1,188.1 | 26.7 | 4.40 | 18.6% | 0.46 | +18.4% | +22.3% |
| Lenskart Solutions Limited | ₹1.16 L Cr | ₹689.7 | 181.4 | 13.30 | 5.6% | 0.35 | +35.4% | — |
| Dr. Reddy's Laboratories Limited | ₹1.14 L Cr | ₹1,374 | 40.6 | 3.02 | 11.4% | 0.21 | +3.2% | +14.5% |
| Cipla Limited | ₹1.13 L Cr | ₹1,402 | 38.9 | 3.27 | 11.3% | 0.02 | +2.1% | -6.7% |
| Mankind Pharma Limited | ₹1.03 L Cr | ₹2,475 | 45.9 | 6.31 | 11.7% | 0.39 | +17.0% | +3.1% |
| Aurobindo Pharma Limited | ₹98,101.93 Cr | ₹1,705 | 26.6 | 2.59 | 9.2% | 0.21 | +6.4% | +48.4% |
| Gian Life Care Limited | ₹4.43 Cr | ₹4.25 | — | 0.23 | -0.2% | 0.30 | -49.5% | -65.2% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.